Showing all 8 results
The NGS Colorectal Cancer Panel from Lab Tests Dubai is a state-of-the-art genetic test that decodes the unique mutations in your tumor, unlocking critical insights for personalized treatment, targeted therapy selection, and hereditary risk assessment.
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
Mitochondrial DNA (mtDNA) Sequencing provides high-resolution analysis of mitochondrial genomes, enabling precise identification of genetic variations. Key features include full-length mtDNA sequencing, high accuracy, and deep coverage, ensuring reliable detection of mutations and heteroplasmy. Benefits include applications in ancestry research, forensic identification, disease association studies, and evolutionary biology.
The Oncomine Acute Myeloid Leukaemia (AML) Panel is a cutting-edge genetic test that provides a full genomic picture of AML, helping doctors pinpoint key mutations, gene fusions, and copy number changes in genes known to drive the disease. Using advanced next-generation sequencing (NGS), this test delivers fast, precise results, even from limited or degraded sample, so patients get an accurate diagnosis and tailored treatment plans sooner.
The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes.
The Oncomine Myeloproliferative Neoplasm (MPN) Panel is a cutting-edge genetic test that analyzes key mutations in JAK2, CALR, and MPL, the genes most commonly linked to myeloproliferative disorders. Using advanced next-generation sequencing (NGS), this test provides a highly accurate and efficient way to diagnose and classify MPNs, even when only small or degraded samples are available (as little as 10 ng of DNA or RNA).
Whole Exome Sequencing (WES) is a powerful genetic testing method that sequences all protein-coding regions (exons) of the genome, covering approximately 1-2% of the DNA where most disease-causing mutations occur. It offers a cost-effective alternative to whole genome sequencing while providing high-depth coverage for accurate variant detection. WES enables the identification of genetic mutations linked to inherited disorders, cancer, and rare diseases, making it a valuable tool for clinical diagnostics, personalized medicine, and research.